<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7094090/results/search/disease/results.xml">
  <result pre="courier ; font-style : italic;} ACS Cent SciACS Cent SciocacsciiACS" exact="Central" post="Science2374-79432374-7951American Chemical Society pmcid: 7094090 pmid: 32226821 doi: 10.1021/acscentsci.0c00272"/>
  <result pre="Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus" exact="Diseases" post="LiuCynthia*ZhouQiongqiongLiYingzhuGarnerLinda V.WatkinsSteve P.CarterLinda J.SmootJeffreyGreggAnne C.DanielsAngela D.JerveySusanAlbaiuDana[], CAS, a division"/>
  <result pre="V.WatkinsSteve P.CarterLinda J.SmootJeffreyGreggAnne C.DanielsAngela D.JerveySusanAlbaiuDana[], CAS, a division of the" exact="American" post="Chemical SocietyUnited States *Email: cliu@cas.org. epub: 2020-03-03ppub: 2020-03-0363315331received: 2020-03-06accepted:"/>
  <result pre="SocietyUnited States *Email: cliu@cas.org. epub: 2020-03-03ppub: 2020-03-0363315331received: 2020-03-06accepted: 2020-03-09rev-recd: 2020-03-09(C)" exact="American" post="Chemical Society, 2020This article is made available via the"/>
  <result pre="as a global pandemic. Background The outbreak of the novel" exact="coronavirus disease," post="COVID-19, caused by the new coronavirus 2019-nCoV that is"/>
  <result pre="new coronavirus 2019-nCoV that is now officially designated as severe" exact="acute" post="respiratory syndrome-related coronavirus SARS-CoV-2, represents a pandemic threat to"/>
  <result pre="coronavirus 2019-nCoV that is now officially designated as severe acute" exact="respiratory" post="syndrome-related coronavirus SARS-CoV-2, represents a pandemic threat to global"/>
  <result pre="in December of 2019 was located in Wuhan, China, this" exact="disease" post="has spread to more than 100 countries (Figure 1)"/>
  <result pre="of confirmed COVID-19 cases. (Map was reproduced from WHO Coronavirus" exact="Disease" post="(COVID-2019) Situation Reports.3 Used with permission from ref (3)."/>
  <result pre="through March 9, 2020. (Data were obtained from WHO Coronavirus" exact="Disease" post="(COVID-2019) Situation Reports3). Coronaviruses (CoVs) are relatively large viruses"/>
  <result pre="single-stranded positive-sense RNA genome encapsulated within a membrane envelope. The" exact="viral" post="membrane is studded with glycoprotein spikes that give coronaviruses"/>
  <result pre="alpha, beta, gamma, and delta. The betacoronavirus class includes severe" exact="acute" post="respiratory syndrome (SARS) virus (SARS-CoV), Middle East respiratory syndrome"/>
  <result pre="beta, gamma, and delta. The betacoronavirus class includes severe acute" exact="respiratory" post="syndrome (SARS) virus (SARS-CoV), Middle East respiratory syndrome (MERS)"/>
  <result pre="gamma, and delta. The betacoronavirus class includes severe acute respiratory" exact="syndrome" post="(SARS) virus (SARS-CoV), Middle East respiratory syndrome (MERS) virus"/>
  <result pre="includes severe acute respiratory syndrome (SARS) virus (SARS-CoV), Middle East" exact="respiratory" post="syndrome (MERS) virus (MERS-CoV), and the COVID-19 causative agent"/>
  <result pre="severe acute respiratory syndrome (SARS) virus (SARS-CoV), Middle East respiratory" exact="syndrome" post="(MERS) virus (MERS-CoV), and the COVID-19 causative agent SARS-CoV-2."/>
  <result pre="agent SARS-CoV-2. Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 attacks the" exact="lower" post="respiratory system to cause viral pneumonia, but it may"/>
  <result pre="SARS-CoV-2. Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 attacks the lower" exact="respiratory" post="system to cause viral pneumonia, but it may also"/>
  <result pre="and MERS-CoV, SARS-CoV-2 attacks the lower respiratory system to cause" exact="viral pneumonia," post="but it may also affect the gastrointestinal system, heart,"/>
  <result pre="may also affect the gastrointestinal system, heart, kidney, liver, and" exact="central nervous system" post="leading to multiple organ failure.6,7 Current information indicates that"/>
  <result pre="SARS-CoV.8 Figure 3 Cartoon illustration of the coronavirus structure and" exact="viral" post="receptor ACE2 on the host cell surface. (Image was"/>
  <result pre="by the host cell-produced serine protease TMPRSS211. In addition, the" exact="viral" post="genome also encodes several nonstructural proteins including RNA-dependent RNA"/>
  <result pre="papain-like protease (PLpro).12,13 Upon entrance to the host cells, the" exact="viral" post="genome is released as a single-stranded positive RNA. Subsequently,"/>
  <result pre="as a single-stranded positive RNA. Subsequently, it is translated into" exact="viral" post="polyproteins using host cell protein translation machinery, which are"/>
  <result pre="translation machinery, which are then cleaved into effector proteins by" exact="viral" post="proteinases 3CLpro and PLpro.12,13 PLpro also behaves as a"/>
  <result pre="RNA template to be used by RdRp to make more" exact="viral" post="genomic RNA. The interaction between viral S protein and"/>
  <result pre="RdRp to make more viral genomic RNA. The interaction between" exact="viral" post="S protein and ACE2 on the host cell surface"/>
  <result pre="cell surface is of significant interest since it initiates the" exact="infection" post="process. Cryo-EM structure analysis has revealed that the binding"/>
  <result pre="and preventive agents for COVID-19, CAS, a division of the" exact="American" post="Chemical Society specializing in scientific information solutions, has analyzed"/>
  <result pre="Related to COVID-19 Since the outbreak of COVID-19, this new" exact="disease" post="and its causative virus have drawn major global attention."/>
  <result pre="been conducting a major campaign to understand this new emergent" exact="disease" post="and its epidemiology in an effort to uncover possible"/>
  <result pre="effective therapeutic agents, and develop vaccines. Figure 4 shows the" exact="total" post="number of journal articles related to COVID-19 or SARS-CoV-2"/>
  <result pre="identify new methods to halt the progression of this epidemic" exact="disease" post="and to prevent infection and transmission in the future."/>
  <result pre="halt the progression of this epidemic disease and to prevent" exact="infection" post="and transmission in the future. Figure 4 Number of"/>
  <result pre="England Journal of Medicine A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019 January 24, 2020 NHC Key Laboratory"/>
  <result pre="NHC Key Laboratory of Biosafety, China, and National Institute for" exact="Viral" post="Disease Control, Chinese Center for Disease Control and Prevention,"/>
  <result pre="Key Laboratory of Biosafety, China, and National Institute for Viral" exact="Disease" post="Control, Chinese Center for Disease Control and Prevention, Beijing,"/>
  <result pre="and National Institute for Viral Disease Control, Chinese Center for" exact="Disease" post="Control and Prevention, Beijing, Chinab 2 Lancet Clinical features"/>
  <result pre="novel coronavirus in Wuhan, China January 24, 2020 Department of" exact="Pulmonary" post="and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China;"/>
  <result pre="Medicine Early transmission dynamics in Wuhan, China, of novel coronavirus-infected" exact="pneumonia" post="January 29, 2020 Chinese Center for Disease Control and"/>
  <result pre="of novel coronavirus-infected pneumonia January 29, 2020 Chinese Center for" exact="Disease" post="Control and Prevention, Beijing, China; School of Public Health,"/>
  <result pre="Health, University of Hong Kong, Hong Kong; Hubei Center for" exact="Disease" post="Control and Prevention, Wuhan, Hubei, Chinab 5 Journal of"/>
  <result pre="Epidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive study January 30, 2020"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study January 30, 2020"/>
  <result pre="pneumonia in Wuhan, China: a descriptive study January 30, 2020" exact="Tuberculosis" post="and Respiratory Department, Wuhan Jinyintan Hospital, Wuhan, China 7"/>
  <result pre="Wuhan, China: a descriptive study January 30, 2020 Tuberculosis and" exact="Respiratory" post="Department, Wuhan Jinyintan Hospital, Wuhan, China 7 The New"/>
  <result pre="30, 2020 NHC Key Laboratory of Biosafety, National Institute for" exact="Viral" post="Disease Control and Prevention, Chinese Center for Disease Control"/>
  <result pre="2020 NHC Key Laboratory of Biosafety, National Institute for Viral" exact="Disease" post="Control and Prevention, Chinese Center for Disease Control and"/>
  <result pre="Institute for Viral Disease Control and Prevention, Chinese Center for" exact="Disease" post="Control and Prevention, Beijing, China, Central Theater, People’s Liberation"/>
  <result pre="Prevention, Chinese Center for Disease Control and Prevention, Beijing, China," exact="Central" post="Theater, People’s Liberation Army General Hospital, Wuhan, China, Center"/>
  <result pre="Control and Prevention, Beijing, China, Central Theater, People’s Liberation Army" exact="General" post="Hospital, Wuhan, China, Center for Biosafety Mega-Science, Chinese Academy"/>
  <result pre="Kong, Chinab 10 Nature A new coronavirus associated with human" exact="respiratory" post="disease in China February 3, 2020 Shanghai Public Health"/>
  <result pre="Chinab 10 Nature A new coronavirus associated with human respiratory" exact="disease" post="in China February 3, 2020 Shanghai Public Health Clinical"/>
  <result pre="of Public Health, Fudan University, Shanghai, Chinab 11 Nature A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="Wuhan, Chinab 12 Lancet Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease February 4, 2020 BenevolentAI, London, UK and"/>
  <result pre="Chinab 12 Lancet Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease February 4, 2020 BenevolentAI, London, UK and Department"/>
  <result pre="12 Lancet Baricitinib as potential treatment for 2019-nCoV acute respiratory" exact="disease" post="February 4, 2020 BenevolentAI, London, UK and Department of"/>
  <result pre="of Pharmacology and Toxicology, Beijing, Chinab 14 Emerging Microbes &amp;amp;" exact="Infections" post="RNA based mNGS approach identifies a novel human coronavirus"/>
  <result pre="mNGS approach identifies a novel human coronavirus from two individual" exact="pneumonia" post="cases in 2019 Wuhan outbreak February 5, 2020 State"/>
  <result pre="Sciences, Wuhan University, Wuhan, Chinab 15 The Journal of the" exact="American" post="Medical Association Clinical characteristics of 138 hospitalized patients with"/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China February 7, 2020 Department of Critical"/>
  <result pre="(2019-nCoV) originating in China February 7, 2020 National Institute for" exact="Viral" post="Disease Control and Prevention, China CDC, Beijing, China; Department"/>
  <result pre="originating in China February 7, 2020 National Institute for Viral" exact="Disease" post="Control and Prevention, China CDC, Beijing, China; Department of"/>
  <result pre="of Medical Molecular Virology, School of Basic Medical Sciences, Fudan-Jinbo" exact="Joint" post="Research Center, Fudan University, Shanghai, China aNote: The publication"/>
  <result pre="of coronavirus in the same genus as SARS-CoV and MERS-CoV." exact="Viral" post="proteins responsible for SARS-CoV-2 entry into host cells and"/>
  <result pre="AND RELATED CORONAVIRUS DISEASES Key Proteins and Their Roles in" exact="Viral Infection" post="Identification of targets is important for identifying drugs with"/>
  <result pre="RELATED CORONAVIRUS DISEASES Key Proteins and Their Roles in Viral" exact="Infection" post="Identification of targets is important for identifying drugs with"/>
  <result pre="SARS-CoV-2 infection. Table 2 lists potential targets, their roles in" exact="viral infection," post="and representative existing drugs or drug candidates that reportedly"/>
  <result pre="their effects on SARS-CoV-2 infection. 3CLpro and PLpro are two" exact="viral" post="proteases responsible for the cleavage of viral peptides into"/>
  <result pre="PLpro are two viral proteases responsible for the cleavage of" exact="viral" post="peptides into functional units for virus replication and packaging"/>
  <result pre="have been explored.19 RdRp is the RNA polymerase responsible for" exact="viral" post="RNA synthesis that may be blocked by existing antiviral"/>
  <result pre="or drug candidates, such as remdesivir.19 Conceivably, the interaction of" exact="viral" post="S protein with its receptor ACE2 on host cells,"/>
  <result pre="protein with its receptor ACE2 on host cells, and subsequent" exact="viral" post="endocytosis into the cells, may also be a viable"/>
  <result pre="which functions as a virus-host cell fusion inhibitor to prevent" exact="viral" post="entry into host cells against influenza virus,20 has entered"/>
  <result pre="COVID-19.11 Table 2 Key Proteins and Their Roles during the" exact="Viral Infection" post="Process target candidate full name role during viral infection"/>
  <result pre="Table 2 Key Proteins and Their Roles during the Viral" exact="Infection" post="Process target candidate full name role during viral infection"/>
  <result pre="the Viral Infection Process target candidate full name role during" exact="viral infection" post="drug candidate 3CLpro coronavirus main protease 3CLpro a protease"/>
  <result pre="Viral Infection Process target candidate full name role during viral" exact="infection" post="drug candidate 3CLpro coronavirus main protease 3CLpro a protease"/>
  <result pre="coronavirus main protease 3CLpro a protease for the proteolysis of" exact="viral" post="polyprotein into functional units lopinavir19,30 PLpro papain-like protease PLpro"/>
  <result pre="PLpro papain-like protease PLpro a protease for the proteolysis of" exact="viral" post="polyprotein into functional units lopinavir19,30 RdRp RNA-dependent RNA polymerase"/>
  <result pre="RdRp RNA-dependent RNA polymerase an RNA-dependent RNA polymerase for replicating" exact="viral" post="genome remdesivir,19,29,32 ribavirin16,29,31 S protein viral spike glycoprotein a"/>
  <result pre="RNA polymerase for replicating viral genome remdesivir,19,29,32 ribavirin16,29,31 S protein" exact="viral" post="spike glycoprotein a viral surface protein for binding to"/>
  <result pre="viral genome remdesivir,19,29,32 ribavirin16,29,31 S protein viral spike glycoprotein a" exact="viral" post="surface protein for binding to host cell receptor ACE2"/>
  <result pre="binding to ACE2 camostat mesylate11 ACE2 angiotensin-converting enzyme 2 a" exact="viral" post="receptor protein on the host cells which binds to"/>
  <result pre="viral receptor protein on the host cells which binds to" exact="viral" post="S protein Arbidol20,22,33a AT2 angiotensin AT2 receptor an important"/>
  <result pre="in the regulation of blood pressure and volume of the" exact="cardiovascular" post="system L-16349128 aAn inhibitor of viral entry to host"/>
  <result pre="and volume of the cardiovascular system L-16349128 aAn inhibitor of" exact="viral" post="entry to host cells. Its direct action on S"/>
  <result pre="and ACE2 is yet to be confirmed. ACE2 involvement with" exact="coronavirus infection" post="is of further interest since ACE2 is a potent"/>
  <result pre="ACE2 is yet to be confirmed. ACE2 involvement with coronavirus" exact="infection" post="is of further interest since ACE2 is a potent"/>
  <result pre="system (RAS) that may be involved in elicitation of inflammatory" exact="lung disease" post="in addition to its well-known role in regulation of"/>
  <result pre="(RAS) that may be involved in elicitation of inflammatory lung" exact="disease" post="in addition to its well-known role in regulation of"/>
  <result pre="AT2 receptors are altered in coronavirus-induced diseases due to the" exact="limited" post="number of studies.23,24 Therefore, it is yet to be"/>
  <result pre="that target any of these proteins (e.g., L-163491 as a" exact="partial" post="antagonist of AT1 receptor and partial agonist of AT2"/>
  <result pre="(e.g., L-163491 as a partial antagonist of AT1 receptor and" exact="partial" post="agonist of AT2 receptor) may alleviate coronavirus-induced lung injury.28"/>
  <result pre="lung injury.28 Patents and Potential Drug Candidates Related to Key" exact="Protein" post="Targets The CAS content collection contains patents related to"/>
  <result pre="SARS-CoV which also contains 3CLpro and RdRp. Table 3 Key" exact="Protein" post="Targets and Related Patents in the CAS Content Collection"/>
  <result pre="because of its anti-inflammatory effect and possible ability to reduce" exact="viral" post="entry.35 A fixed dose of the anti-HIV combination, lopinavir–ritonavir,"/>
  <result pre="Sciences Inc., was previously tested in humans with Ebola virus" exact="disease" post="and has shown promise in animal models for MERS"/>
  <result pre="and the USA. Favipiravir, a purine nucleoside leading to inaccurate" exact="viral" post="RNA synthesis,36 was originally developed by Toyama Chemical of"/>
  <result pre="candidate CAS RN target possible mechanism of action on COVID-19" exact="disease" post="indication baricitinib35 1187594-09-7 JAK kinase a JAK inhibitor that"/>
  <result pre="that may interfere with the inflammatory processes approved drug for" exact="rheumatoid arthritis" post="lopinavir19a 192725-17-0 viral proteases: 3CLpro or PLpro protease inhibitors"/>
  <result pre="may interfere with the inflammatory processes approved drug for rheumatoid" exact="arthritis" post="lopinavir19a 192725-17-0 viral proteases: 3CLpro or PLpro protease inhibitors"/>
  <result pre="the inflammatory processes approved drug for rheumatoid arthritis lopinavir19a 192725-17-0" exact="viral" post="proteases: 3CLpro or PLpro protease inhibitors that may inhibit"/>
  <result pre="proteases: 3CLpro or PLpro protease inhibitors that may inhibit the" exact="viral" post="proteases: 3CLpro or PLpro lopinavir and ritonavir are approved"/>
  <result pre="or PLpro lopinavir and ritonavir are approved drug combination for" exact="HIV infection" post="ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for HIV infection"/>
  <result pre="PLpro lopinavir and ritonavir are approved drug combination for HIV" exact="infection" post="ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for HIV infection"/>
  <result pre="for HIV infection ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for" exact="HIV infection" post="favipiravir (favilavir)29,36 259793-96-9 RdRp a purine nucleoside that acts"/>
  <result pre="HIV infection ritonavir19,37c 155213-67-5 darunavir33 206361-99-1 approved drug for HIV" exact="infection" post="favipiravir (favilavir)29,36 259793-96-9 RdRp a purine nucleoside that acts"/>
  <result pre="nucleoside that acts as an alternate substrate leading to inaccurate" exact="viral" post="RNA synthesis viral infections remdesivir19,29,32a 1809249-37-3 a nucleotide analogue"/>
  <result pre="as an alternate substrate leading to inaccurate viral RNA synthesis" exact="viral" post="infections remdesivir19,29,32a 1809249-37-3 a nucleotide analogue that may block"/>
  <result pre="an alternate substrate leading to inaccurate viral RNA synthesis viral" exact="infections" post="remdesivir19,29,32a 1809249-37-3 a nucleotide analogue that may block viral"/>
  <result pre="viral infections remdesivir19,29,32a 1809249-37-3 a nucleotide analogue that may block" exact="viral" post="nucleotide synthesis to stop viral replication Ebola virus infection"/>
  <result pre="nucleotide analogue that may block viral nucleotide synthesis to stop" exact="viral" post="replication Ebola virus infection ribavirin16,29−31a 36791-04-5 RSV infection, hepatitis"/>
  <result pre="may block viral nucleotide synthesis to stop viral replication Ebola" exact="virus infection" post="ribavirin16,29−31a 36791-04-5 RSV infection, hepatitis C, some viral hemorrhagic"/>
  <result pre="block viral nucleotide synthesis to stop viral replication Ebola virus" exact="infection" post="ribavirin16,29−31a 36791-04-5 RSV infection, hepatitis C, some viral hemorrhagic"/>
  <result pre="stop viral replication Ebola virus infection ribavirin16,29−31a 36791-04-5 RSV infection," exact="hepatitis" post="C, some viral hemorrhagic fevers galidesivir34b 249503-25-1 hepatitis C,"/>
  <result pre="Ebola virus infection ribavirin16,29−31a 36791-04-5 RSV infection, hepatitis C, some" exact="viral" post="hemorrhagic fevers galidesivir34b 249503-25-1 hepatitis C, Ebola virus, Marburg"/>
  <result pre="RSV infection, hepatitis C, some viral hemorrhagic fevers galidesivir34b 249503-25-1" exact="hepatitis" post="C, Ebola virus, Marburg virus BCX-4430 (salt form of"/>
  <result pre="Ebola virus, Marburg virus BCX-4430 (salt form of galidesivir)34b 222631-44-9" exact="hepatitis" post="C, Ebola virus, Marburg virus Arbidol22,33a 131707-23-8 S protein/ACE2d"/>
  <result pre="S protein/ACE2d an inhibitor that may disrupt the binding of" exact="viral" post="envelope protein to host cells and prevent viral entry"/>
  <result pre="binding of viral envelope protein to host cells and prevent" exact="viral" post="entry to the target cell influenza antiviral drug chloroquine29,32"/>
  <result pre="elevate endosomal pH and interfere with ACE2 glycosylation malarial parasite" exact="infection" post="nitazoxanide29 55981-09-4 N/A a drug that may inhibit viral"/>
  <result pre="parasite infection nitazoxanide29 55981-09-4 N/A a drug that may inhibit" exact="viral" post="protein expression various helminthic, protozoal, and viral infection-caused diarrhea"/>
  <result pre="that may inhibit viral protein expression various helminthic, protozoal, and" exact="viral" post="infection-caused diarrhea aDrugs under clinical trials for treating COVID-19"/>
  <result pre="inhibit viral protein expression various helminthic, protozoal, and viral infection-caused" exact="diarrhea" post="aDrugs under clinical trials for treating COVID-19 (repurposing). bDrugs"/>
  <result pre="is used in combination with antivirial Lopinavir.37 dAn inhibitor of" exact="viral" post="entry to host cells. Its direct action on S"/>
  <result pre="synthetic preparation role assigned by CAS scientists during document indexing." exact="Patent" post="applications WO2009114512 and WO2014028756 disclose preparation of compounds active"/>
  <result pre="later named as baricitinib and developed for reducing inflammation in" exact="rheumatoid arthritis." post="Patent application JP5971830 discloses preparation of polycyclic pyridone compounds"/>
  <result pre="as baricitinib and developed for reducing inflammation in rheumatoid arthritis." exact="Patent" post="application JP5971830 discloses preparation of polycyclic pyridone compounds and"/>
  <result pre="of polycyclic pyridone compounds and their use as endonuclease inhibitors." exact="Patent" post="applications US20160122374 and US20170071964 disclose preparation of the nucleotide"/>
  <result pre="developed as a therapeutic agent for Ebola and Marburg virus" exact="infections" post="(Patent US20170071964). Because of its promising results in at"/>
  <result pre="20141029 Preparation of nucleosides and methods for treating Filoviridae virus" exact="infections" post="Gilead Sciences, Inc., USA US20170071964 20160916 Preparation of amino"/>
  <result pre="acid-containing nucleotides and methods for treating arenaviridae and coronaviridae virus" exact="infections" post="Gilead Sciences, Inc., USA WO2007075145 20070704 Preparation of benzopyranone"/>
  <result pre="3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid derivatives as cysLT2 receptor antagonists for treatment of" exact="respiratory" post="diseases Ono Pharmaceutical Co., Ltd., Japan WO2007120160 20071025 Preparation"/>
  <result pre="Ltd., Japan WO2007120160 20071025 Preparation of N-heterocyclic acetamides useful for" exact="viral" post="inhibition Novartis AG, USA WO2009119167 20091001 Aniline derivative having"/>
  <result pre="inhibition Novartis AG, USA WO2009119167 20091001 Aniline derivative having anti-RNA" exact="viral" post="activity KinoPharma, Inc., Japan WO2013049382 20130404 Broad-spectrum antivirals against"/>
  <result pre="selective and potent glycosidase inhibitors: new structures for antivirals and" exact="osteoarthritis" post="therapeutics Academia Sinica, Taiwan Patent application WO2013049382 discloses both"/>
  <result pre="new structures for antivirals and osteoarthritis therapeutics Academia Sinica, Taiwan" exact="Patent" post="application WO2013049382 discloses both structures and syntheses of compounds"/>
  <result pre="heterocycles), as well as certain formulation compositions, developed to inhibit" exact="viral" post="3C protease or 3C-like protease (i.e., 3CLpro). Patent application"/>
  <result pre="to inhibit viral 3C protease or 3C-like protease (i.e., 3CLpro)." exact="Patent" post="application WO2018042343 presents both preparation methods and biological assay"/>
  <result pre="infected with a specified virus (e.g., MERS virus) expressing the" exact="viral" post="S protein. Drug administration routes were also mentioned in"/>
  <result pre="Compounds in Research and Development with Potential Effects on Key" exact="Protein" post="Targets for Human Coronavirus-Induced Diseases Besides various commercialized antiviral"/>
  <result pre="with Potential Effects on Key Protein Targets for Human Coronavirus-Induced" exact="Diseases" post="Besides various commercialized antiviral drugs, there are also small"/>
  <result pre="SARS-CoV and MERS-CoV (Table 6). These drug candidates mostly inhibit" exact="viral" post="enzymes including proteases and components for RdRp. Since 3CLpro"/>
  <result pre="C-473872, NSC-306711 and N-65828, which may inhibit the activity of" exact="viral" post="NSP15, poly(U)-specific endoribonuclease, were tested for reduced SARS-CoV infectivity"/>
  <result pre="two AT2 agonists, whereas L-163491 has dual functions as a" exact="partial" post="agonist for AT2 receptor and a partial antagonist of"/>
  <result pre="functions as a partial agonist for AT2 receptor and a" exact="partial" post="antagonist of AT1 receptor. Since AT1 and AT2 are"/>
  <result pre="balance between AT1 and AT2, which may be affected by" exact="coronavirus infection" post="and to alleviate viral-induced lung injury during the infection.24"/>
  <result pre="between AT1 and AT2, which may be affected by coronavirus" exact="infection" post="and to alleviate viral-induced lung injury during the infection.24"/>
  <result pre="RNA-dependent RNA polymerase (RdRp) an inhibitor that may bind to" exact="viral" post="RdRp, as tested against SARS-CoV in cell culture16 502960-90-9"/>
  <result pre="tested against SARS-CoV in cell culture16 502960-90-9 4-methyl-N-[(1S)-2-oxo-2 [[(1S,2E)-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl]amino]-1-(phenylmethyl)ethyl]- 1-piperazinecarboxamide" exact="viral" post="proteases: 3CLpro and PLpro an inhibitor that may disrupt"/>
  <result pre="disrupt the function of 3CLpro and PLpro41 2409054-43-7 (αR)-α-[[3-(4-chloro-2-fluorophenyl)-1-oxo-2-propen-1-yl]amino]-N-[(1R)-1-methyl-2-(2-oxo-3-pyrrolidinyl)ethyl]- benzenepropanamide" exact="viral" post="proteases: 3CLpro or PLpro an inhibitor that may disrupt"/>
  <result pre="benzopurpurin B NSP15 (poly(U)-specific endoribonuclease) chemical inhibitors that may suppress" exact="viral" post="infectivity by inhibiting endoribonuclease NSP15, as tested against SARS-CoV"/>
  <result pre="170969-73-0 L-163491 a dual-property molecule that functions as angiotensin AT1" exact="partial" post="antagonist and AT2 agonist which may alleviate the virus-induced"/>
  <result pre="and ongoing epidemiological problems around the world. Since there is" exact="limited" post="clinical and basic research information at this time, treatment"/>
  <result pre="and cytokines (22). Given the indispensable role of vaccines in" exact="viral" post="disease prevention, detailed analysis of vaccines will be presented"/>
  <result pre="cytokines (22). Given the indispensable role of vaccines in viral" exact="disease" post="prevention, detailed analysis of vaccines will be presented in"/>
  <result pre="receptor in order to gain access into host cells.42 In" exact="viral infection," post="the S protein, but not the other structural proteins,"/>
  <result pre="attachment signals or GPI against enveloped virus such as HIV," exact="avian flu," post="SARS or Ebola virus Institute Pasteur of Shanghai 20080229"/>
  <result pre="coronavirus and methods of use thereof Humab, LLC 20080117 WO2008035894" exact="viral infection" post="Preparation of antiviral antibody 3D8 fragments and their use"/>
  <result pre="and methods of use thereof Humab, LLC 20080117 WO2008035894 viral" exact="infection" post="Preparation of antiviral antibody 3D8 fragments and their use"/>
  <result pre="antiviral antibody 3D8 fragments and their use in treatment of" exact="viral infection" post="Sung Kyun Kwan University; Ajou University; Invitroplant Co., Ltd."/>
  <result pre="antibody 3D8 fragments and their use in treatment of viral" exact="infection" post="Sung Kyun Kwan University; Ajou University; Invitroplant Co., Ltd."/>
  <result pre="monoclonal anti-spike protein antibodies for diagnosis and treatment of SARS-coronavirus-associated" exact="disease" post="and screening of vaccine or anti-SARS agent Dana-Farber Cancer"/>
  <result pre="SARS-coronavirus-associated disease and screening of vaccine or anti-SARS agent Dana-Farber" exact="Cancer" post="Institute 20051007 CN1911963 RBD of S protein Method for"/>
  <result pre="S protein Method for preparing neutralizing monoclonal antibody against severe" exact="acute" post="respiratory syndrome coronavirus and its application Chinese Academy of"/>
  <result pre="protein Method for preparing neutralizing monoclonal antibody against severe acute" exact="respiratory" post="syndrome coronavirus and its application Chinese Academy of Sciences"/>
  <result pre="Method for preparing neutralizing monoclonal antibody against severe acute respiratory" exact="syndrome" post="coronavirus and its application Chinese Academy of Sciences 20050810"/>
  <result pre="California 20050310 WO2006086561 spike protein Neutralizing monoclonal antibodies against severe" exact="acute" post="respiratory syndrome-associated coronavirus New York Blood Center, Inc. 20050208"/>
  <result pre="20050310 WO2006086561 spike protein Neutralizing monoclonal antibodies against severe acute" exact="respiratory" post="syndrome-associated coronavirus New York Blood Center, Inc. 20050208 CN1664100"/>
  <result pre="monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus New York" exact="Blood" post="Center, Inc. 20050208 CN1664100 spike protein Preparation of heavy"/>
  <result pre="N protein and its use in treatment of SARS virus" exact="infections" post="Chinese Academy of Sciences 20040715 US20060240551 spike protein Neutralizing"/>
  <result pre="Sciences 20040715 US20060240551 spike protein Neutralizing monoclonal antibodies against severe" exact="acute" post="respiratory syndrome-associated coronavirus New York Blood Center, Inc. 20040602"/>
  <result pre="20040715 US20060240551 spike protein Neutralizing monoclonal antibodies against severe acute" exact="respiratory" post="syndrome-associated coronavirus New York Blood Center, Inc. 20040602 WO2005054469"/>
  <result pre="monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus New York" exact="Blood" post="Center, Inc. 20040602 WO2005054469 spike protein Anti-SARS-coronavirus monoclonal antibodies,"/>
  <result pre="and for screening of epitopic vaccines or anti-SARS therapeutics Dana-Farber" exact="Cancer" post="Institute, Inc. 20031125 US20050106563 spike protein Epitope profiles of"/>
  <result pre="for use in antigen detection, antibody production, and defense against" exact="infection" post="Genesis Biotech Inc. 20030908 US20050069869 spike protein SARS coronavirus"/>
  <result pre="thereof University of Massachusetts 20030804 WO2005012360 S and N proteins" exact="Antibody" post="binding molecules specific for SARS coronavirus Crucell Holland BV"/>
  <result pre="Crucell Holland BV 20030722 CN1566155 S, N, and M proteins" exact="Antibody" post="library-derived human monoclonal anti-SARS virus antibodies for treating severe"/>
  <result pre="Antibody library-derived human monoclonal anti-SARS virus antibodies for treating severe" exact="acute" post="respiratory syndrome Igcon Therapeutics Co., Ltd.; Genetastix Corporation 20030710"/>
  <result pre="library-derived human monoclonal anti-SARS virus antibodies for treating severe acute" exact="respiratory" post="syndrome Igcon Therapeutics Co., Ltd.; Genetastix Corporation 20030710 WO2005007671"/>
  <result pre="human monoclonal anti-SARS virus antibodies for treating severe acute respiratory" exact="syndrome" post="Igcon Therapeutics Co., Ltd.; Genetastix Corporation 20030710 WO2005007671 spike"/>
  <result pre="protein 10). Cytokine storm has been reported to correlate with" exact="disease" post="severity in SARS-CoV-2 infection. Patients admitted to an ICU"/>
  <result pre="from T helper 2 cells such as IL-4 and IL-10.44" exact="Patent" post="application WO2005058815 discloses human anti-IP-10 antibodies, including bispecific molecules"/>
  <result pre="that bind to IP-10 with high affinity, for treating inflammation," exact="autoimmune" post="disease, neurodegenerative disease, bacterial infection, and viral infection. Patent"/>
  <result pre="with high affinity, for treating inflammation, autoimmune disease, neurodegenerative disease," exact="bacterial infection," post="and viral infection. Patent application WO2017095875 discloses the preparation"/>
  <result pre="for treating inflammation, autoimmune disease, neurodegenerative disease, bacterial infection, and" exact="viral infection." post="Patent application WO2017095875 discloses the preparation of human antibodies"/>
  <result pre="inflammation, autoimmune disease, neurodegenerative disease, bacterial infection, and viral infection." exact="Patent" post="application WO2017095875 discloses the preparation of human antibodies and"/>
  <result pre="at 10 mg/kg in Cynomolgus macaques. In addition, DC-SIGN/CD209, a" exact="type II" post="transmembrane adhesion molecule with C-type lectin function, is mainly"/>
  <result pre="cofactor in transferring SARS-CoV to susceptible cells such as pneumocytes.46" exact="Patent" post="application WO200505824 claims the production of a humanized anti-DC-SIGN"/>
  <result pre="of DC-SIGN with its receptor, ICAM-3. The antibody effectively blocked" exact="viral" post="binding, infection, and transmission for viral infections/diseases, including SARS."/>
  <result pre="The antibody effectively blocked viral binding, infection, and transmission for" exact="viral" post="infections/diseases, including SARS. Cytokines Cytokines are low-molecular-weight proteins that"/>
  <result pre="cytokines associated with 76 724 documents, including 11 837 patents. During a" exact="viral infection," post="the most prominent cytokines produced are IFNs, which interfere"/>
  <result pre="the most prominent cytokines produced are IFNs, which interfere with" exact="viral" post="replication. IFNs are classified as type I (IFN-α, IFN-β,"/>
  <result pre="IFNs, which interfere with viral replication. IFNs are classified as" exact="type I" post="(IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ν, IFN-τ, and IFN-ω),"/>
  <result pre="I (IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ν, IFN-τ, and IFN-ω)," exact="type II" post="(IFN-γ), or type III (IFN-λ) based on the receptor"/>
  <result pre="IFN-ε, IFN-κ, IFN-ν, IFN-τ, and IFN-ω), type II (IFN-γ), or" exact="type III" post="(IFN-λ) based on the receptor complex used for signaling"/>
  <result pre="as sequence homology.47 Because of their ability to interfere with" exact="viral" post="replication, interferons and interferon fusion proteins have been utilized"/>
  <result pre="proteins have been utilized as therapeutic agents for treatment of" exact="viral" post="infections for the past 20 years. A few patents"/>
  <result pre="have been utilized as therapeutic agents for treatment of viral" exact="infections" post="for the past 20 years. A few patents disclosing"/>
  <result pre="and their use for treating SARS are described below. rSIFN-co" exact="Patent" post="applications WO2011072487 and WO2016180335 describe the cloning of a"/>
  <result pre="for determining its potency that was effective for treating various" exact="viral" post="infections/diseases, including SARS. The invention relates that rSIFN-co has"/>
  <result pre="available interferon, but also has significantly stronger antitumor properties against" exact="breast cancer" post="and cervical cancer than other recombinant human α-interferons. The"/>
  <result pre="interferon, but also has significantly stronger antitumor properties against breast" exact="cancer" post="and cervical cancer than other recombinant human α-interferons. The"/>
  <result pre="also has significantly stronger antitumor properties against breast cancer and" exact="cervical cancer" post="than other recombinant human α-interferons. The invention further relates"/>
  <result pre="has significantly stronger antitumor properties against breast cancer and cervical" exact="cancer" post="than other recombinant human α-interferons. The invention further relates"/>
  <result pre="&amp;gt;10 million IU), making it possible to successfully treat some" exact="viral" post="diseases or tumors that require large doses of interferon."/>
  <result pre="diseases or tumors that require large doses of interferon. IFN-ω" exact="Patent" post="application WO2004096852 discloses the amino acid sequence for recombinant"/>
  <result pre="(rhIFN-ω) (RN 791910-34-4) that was shown to have an anti-SARS" exact="viral" post="activity similar to that of IFN-β. IFN-ω effectively decreased"/>
  <result pre="viral activity similar to that of IFN-β. IFN-ω effectively decreased" exact="disease" post="severity and inhibited proliferation of coronavirus strain BJ01 in"/>
  <result pre="in monkeys. IL-28A (IFN-λ2), IL-28B (IFN-λ3), and IL-29 (IFN-λ1) Variants" exact="Patent" post="application WO2005097165 claims a method for treating SARS viral"/>
  <result pre="Variants Patent application WO2005097165 claims a method for treating SARS" exact="viral infection" post="using IL-28A, IL-28B, and IL-29 cysteine variants conjugated to"/>
  <result pre="Patent application WO2005097165 claims a method for treating SARS viral" exact="infection" post="using IL-28A, IL-28B, and IL-29 cysteine variants conjugated to"/>
  <result pre="these variants, MetIL-29C172S-PEG (RN 867228-40-8) was specifically shown to inhibit" exact="viral" post="replication. Interferon-Human Serum Albumin Fusion Protein Patents applications US20090053173"/>
  <result pre="specifically shown to inhibit viral replication. Interferon-Human Serum Albumin Fusion" exact="Protein" post="Patents applications US20090053173 and CN101942026 both disclose long-lasting fusion"/>
  <result pre="cells is typically accomplished by their delivery via plasmids or" exact="viral" post="or bacterial vectors.48 Although microRNAs are noncoding and naturally"/>
  <result pre="typically accomplished by their delivery via plasmids or viral or" exact="bacterial" post="vectors.48 Although microRNAs are noncoding and naturally found in"/>
  <result pre="discussed below. siRNAs Targeting Coronavirus Proteins M, N, or E" exact="Patent" post="application CN101173275 discloses two double-stranded RNAs (dsRNAs) designed to"/>
  <result pre="greater than 70%. Table 9 Representative siRNA Data from Chinese" exact="Patent" post="CN1648249 siRNA sense strand (CAS RN) antisense strand (CAS"/>
  <result pre="The authors demonstrated that SARSi-2, SARSi-3, SARSi-4, and SARSi-7-11 inhibited" exact="coronavirus infection" post="and replication in FRhk-4 cells. SARSi-4 was the most"/>
  <result pre="authors demonstrated that SARSi-2, SARSi-3, SARSi-4, and SARSi-7-11 inhibited coronavirus" exact="infection" post="and replication in FRhk-4 cells. SARSi-4 was the most"/>
  <result pre="in FRhk-4 cells. SARSi-4 was the most effective with nearly" exact="complete" post="inhibition, followed by SARSi-2 and SARSi-3. Patent application CN1569233"/>
  <result pre="effective with nearly complete inhibition, followed by SARSi-2 and SARSi-3." exact="Patent" post="application CN1569233 discloses siRNAs, shown in Table 11, that"/>
  <result pre="the use of RNA aptamers for inhibition of SARS viruses." exact="Patent" post="application KR2009128837 identifies RNA aptamers as anti-SARS agents capable"/>
  <result pre="for the nucleocapsid of SARS-CoV for potential pharmaceutical use. Ribozymes" exact="Patent" post="application JP2007043942 describes a therapeutic RNA/DNA chimeric ribozyme designed"/>
  <result pre="coronaviruses, including SARS. This ribozyme specifically recognizes the GUC in" exact="viral" post="genes with loop conformations. Antisense Oligonucleotides Antisense oligonucleotides have"/>
  <result pre="also been developed to reduce the severity of SARS virus" exact="infections" post="and to prevent or treat SARS virus-associated disease, to"/>
  <result pre="virus in human samples, and to diagnose SARS virus-associated diseases." exact="Patent" post="application WO2005023083 published by Ionis Pharmaceuticals describes hybrid DNA/RNA"/>
  <result pre="the following types: inactive or live-attenuated viruses, virus-like particle (VLP)," exact="viral" post="vectors, protein-based, DNA-based, and mRNA-based vaccines. There are 363"/>
  <result pre="the CAS content collection related to vaccine development to prevent" exact="viral" post="disorders/diseases, including SARS and MERS. Of these, 175 patents"/>
  <result pre="28 patents describe DNA vaccines, 21 patents disclose information on" exact="viral" post="vector vaccines, 13 patents disclose information on VLP vaccines,"/>
  <result pre="patent associated to SARS and MERS. It was reported that" exact="viral" post="S protein subunit vaccines produced higher neutralizing antibody titers"/>
  <result pre="protein subunit vaccines produced higher neutralizing antibody titers and more" exact="complete" post="protection than live-attenuated SARS-CoV, full-length S protein, and DNA-based"/>
  <result pre="receptor binding domain (RBD) of the S1 subunit of the" exact="viral" post="S protein. Collectively, S protein/gene is the preferred target"/>
  <result pre="generating immunity to SARS and MERS follows. Attenuated Virus Vaccines" exact="Patent" post="application US20060039926 discloses live attenuated coronavirus or torovirus vaccines."/>
  <result pre="in mice at day five following intracerebral inoculation. DNA-Based Vaccines" exact="Patent" post="application WO2005081716 discloses compositions and methods for inducing/enhancing immune"/>
  <result pre="were capable of significantly reducing the titer of a challenging" exact="vaccinia" post="vector expressing the N protein of the SARS virus."/>
  <result pre="vaccinia vector expressing the N protein of the SARS virus." exact="Patent" post="application WO2015081155 discloses immunogens, which comprise consensus proteins derived"/>
  <result pre="human trials in the United States in April.57 Protein-Based Vaccines" exact="Patent" post="application WO2010063685 by GlaxoSmithKline (GSK) discloses a vaccine capable"/>
  <result pre="trimerized fusion proteins that can better target previous undruggable pathways." exact="Patent" post="application US20070003577 discloses immunogenic compositions and vaccines associated with"/>
  <result pre="exhibit specific binding to soluble ACE2 receptor; (3) promote antibody-dependent" exact="viral" post="entry in otherwise refractory human Raji B cells; and"/>
  <result pre="Raji B cells; and (4) elicit protection against a challenge" exact="infection" post="in an animal model. Patent application US20060002947 (Antigen Express,"/>
  <result pre="elicit protection against a challenge infection in an animal model." exact="Patent" post="application US20060002947 (Antigen Express, Inc., a subsidiary of Generex)"/>
  <result pre="its Ii-Key immune system activation technology to produce a COVID-19" exact="viral" post="peptide for human clinical trials.53 Virus-like Particle Vaccines In"/>
  <result pre="and SAB-301 were able to protect these mice from MERS-CoV" exact="infection" post="with a single prophylactic injection. Novavax announced on February"/>
  <result pre="approach to prophylactic vaccines include the ability to mimic natural" exact="infection" post="to stimulate a more potent immune response as well"/>
  <result pre="the ability to combine multiple mRNAs into a single vaccine." exact="Patent" post="application WO2017070626 by Moderna discloses mRNA vaccines composed of"/>
  <result pre="by Moderna discloses mRNA vaccines composed of mRNAs encoding antigenic" exact="viral" post="full-length S, S1, or S2 proteins from SARS-CoV and"/>
  <result pre="the full-length S protein reduced more than 90% of the" exact="viral" post="load in the lungs of the rabbits and induced"/>
  <result pre="have been shipped to the National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), a division of the National Institutes of"/>
  <result pre="been shipped to the National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), a division of the National Institutes of Health"/>
  <result pre="Manufacture of this batch was funded by the Coalition for" exact="Epidemic" post="Preparedness Innovations. Patent application WO2018115527 describes vaccines comprising mRNA"/>
  <result pre="batch was funded by the Coalition for Epidemic Preparedness Innovations." exact="Patent" post="application WO2018115527 describes vaccines comprising mRNA encoding at least"/>
  <result pre="as well as biologics targeting complex molecular interactions involved in" exact="coronavirus infection" post="and replication. The drug-repurposing effort summarized in this report"/>
  <result pre="well as biologics targeting complex molecular interactions involved in coronavirus" exact="infection" post="and replication. The drug-repurposing effort summarized in this report"/>
  <result pre="anti-inflammatory drugs. The potential impact of biologics for treatment of" exact="coronavirus infections" post="is promising and includes a wide variety of options"/>
  <result pre="drugs. The potential impact of biologics for treatment of coronavirus" exact="infections" post="is promising and includes a wide variety of options"/>
  <result pre="vaccines for treatment of COVID-19 and coronavirus-related diseases. Because of" exact="limited" post="space, this report devotes minimal attention to current efforts"/>
  <result pre="more efficient and accurate COVID-19 diagnosis methods and products. Novel" exact="infectious diseases" post="resulting from RNA viruses subject to mutation and genetic"/>
  <result pre="as exemplified by COVID-19. Despite two former major outbreaks of" exact="coronavirus infections" post="causing the SARS and MERS respiratory illnesses, the world"/>
  <result pre="exemplified by COVID-19. Despite two former major outbreaks of coronavirus" exact="infections" post="causing the SARS and MERS respiratory illnesses, the world"/>
  <result pre="major outbreaks of coronavirus infections causing the SARS and MERS" exact="respiratory" post="illnesses, the world remains underprepared to effectively manage the"/>
  <result pre="develop effective drugs and vaccines against existing and potential future" exact="coronavirus infections" post="and other highly pathogenic virus outbreaks is necessary to"/>
  <result pre="effective drugs and vaccines against existing and potential future coronavirus" exact="infections" post="and other highly pathogenic virus outbreaks is necessary to"/>
  <result pre="industry include identification of inhibitors aimed at the replication or" exact="infection" post="processes associated with SARS-CoV-2 or other related coronaviruses, as"/>
  <result pre="with SARS-CoV-2 or other related coronaviruses, as well as the" exact="symptomatic" post="results of their infections leading to severe disease and/or"/>
  <result pre="related coronaviruses, as well as the symptomatic results of their" exact="infections" post="leading to severe disease and/or death. The summarized lists,"/>
  <result pre="as the symptomatic results of their infections leading to severe" exact="disease" post="and/or death. The summarized lists, contained in this report,"/>
  <result pre="and the rapid publication rate associated with the SARS-CoV-2 virus-related" exact="disease" post="outbreak, as illustrated in this report, are indicative of"/>
  <result pre="proprietary fingerprints: https://www.cas.org/resources/case-studies/data-quality-impacts-machine-learning References References GorbalenyaA. E.et al.The species severe" exact="acute" post="respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2."/>
  <result pre="fingerprints: https://www.cas.org/resources/case-studies/data-quality-impacts-machine-learning References References GorbalenyaA. E.et al.The species severe acute" exact="respiratory" post="syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature"/>
  <result pre="pandemic or be contained?. Science2020, 367 (6478), 610–611. 10.1126/science.367.6478.610.32029604 Coronavirus" exact="Disease" post="(COVID-2019) Situation Reports 1–45; World Health Organization, 2020.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Coronavirus"/>
  <result pre="XuW.; WuG.; GaoG. F.; TanW.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N. Engl. J. Med.2020, 382 (8),"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. ChemBioChem2020, 21 (5), 730–738."/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. ChemBioChem2020, 21 (5), 730–738. 10.1002/cbic.202000047.32022370"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. ChemBioChem2020, 21 (5), 730–738. 10.1002/cbic.202000047.32022370 ChanJ."/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical" post="pneumonia after visiting Wuhan. Emerging Microbes Infect.2020, 9 (1),"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan. Emerging Microbes Infect.2020, 9 (1), 221–236."/>
  <result pre="and infectivity of 2019-nCoV, a new coronavirus which caused a" exact="pneumonia" post="outbreak in Wuhan, China, bioRxiv2020, 10.1101/2020.01.20.913368. SheahanT. P.; SimsA."/>
  <result pre="Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus" exact="Infection" post="(ELACOI). https://clinicaltrials.gov/ct2/show/NCT04252885. GlowackaI.; BertramS.; HerzogP.; PfefferleS.; SteffenI.; MuenchM. O.;"/>
  <result pre="PohlmannS.Differential downregulation of ACE2 by the spike proteins of severe" exact="acute" post="respiratory syndrome coronavirus and human coronavirus NL63. Journal of"/>
  <result pre="downregulation of ACE2 by the spike proteins of severe acute" exact="respiratory" post="syndrome coronavirus and human coronavirus NL63. Journal of Virology2010,"/>
  <result pre="of ACE2 by the spike proteins of severe acute respiratory" exact="syndrome" post="coronavirus and human coronavirus NL63. Journal of Virology2010, 84"/>
  <result pre="SlutskyA. S.; JiangC.; PenningerJ. M.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failure. Nature2005, 436 (7047), 112–116. 10.1038/nature03712.16001071 TipnisS. R.;"/>
  <result pre="WittB. J; GarrisonE. A; ChampionH. C; KadowitzP. J.L-163,491 is a" exact="partial" post="angiotensin AT(1) receptor agonist in the hindquarters vascular bed"/>
  <result pre="is a partial angiotensin AT(1) receptor agonist in the hindquarters" exact="vascular" post="bed of the cat. Eur. J. Pharmacol.2000, 404 (1-2),"/>
  <result pre="for new enemy: drug repurposing for treatment of newly emerging" exact="viral" post="diseases. Virol. Sin.2020, 10.1007/s12250-020-00204-7. [Epub ahead of print]. MaxmenA.More"/>
  <result pre="and Interferon Therapy for Critically Ill Patients With Middle East" exact="Respiratory" post="Syndrome: A Multicenter Observational Study. Clin. Infect. Dis.2019, DOI:"/>
  <result pre="S.; MinningD. M.; BabuY. S.; SheridanW. P.; BavariS.Protection Against Filovirus" exact="Diseases" post="by a Novel Broad-Spectrum Nucleoside Analogue BCX4430. Nature2014, 508"/>
  <result pre="TuckerC.; SmithD.; OechsleO.; PhelanA.; StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet2020, 395 (10223), e30–e31. 10.1016/S0140-6736(20)30304-4.32032529 MifsudE. J.;"/>
  <result pre="SmithD.; OechsleO.; PhelanA.; StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet2020, 395 (10223), e30–e31. 10.1016/S0140-6736(20)30304-4.32032529 MifsudE. J.; HaydenF."/>
  <result pre="Y.; HuangK.-F.; KimM.; LiangP.-H.Identification and evaluation of potent Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res.2017, 141, 101–106."/>
  <result pre="HuangK.-F.; KimM.; LiangP.-H.Identification and evaluation of potent Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res.2017, 141, 101–106. 10.1016/j.antiviral.2017.02.007.28216367"/>
  <result pre="RobertsA.; VogelL.; SubbaraoK.; MossB.Neutralizing antibody and protective immunity to SARS" exact="coronavirus infection" post="of mice induced by a soluble recombinant polypeptide containing"/>
  <result pre="VogelL.; SubbaraoK.; MossB.Neutralizing antibody and protective immunity to SARS coronavirus" exact="infection" post="of mice induced by a soluble recombinant polypeptide containing"/>
  <result pre="GaneshL.; LeungK.; KongW.-P.; SchwartzO.; SubbaraoK.; NabelG. J.pH-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus is mediated by the spike glycoprotein"/>
  <result pre="LeungK.; KongW.-P.; SchwartzO.; SubbaraoK.; NabelG. J.pH-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus is mediated by the spike glycoprotein andenhanced"/>
  <result pre="KongW.-P.; SchwartzO.; SubbaraoK.; NabelG. J.pH-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus is mediated by the spike glycoprotein andenhanced by"/>
  <result pre="glycoprotein of Marburg virus and the S protein of severe" exact="acute" post="respiratory syndrome coronavirus. J. Virol2004, 78, 12090–12095. 10.1128/JVI.78.21.12090-12095.2004.15479853 The"/>
  <result pre="of Marburg virus and the S protein of severe acute" exact="respiratory" post="syndrome coronavirus. J. Virol2004, 78, 12090–12095. 10.1128/JVI.78.21.12090-12095.2004.15479853 The overview"/>
  <result pre="Marburg virus and the S protein of severe acute respiratory" exact="syndrome" post="coronavirus. J. Virol2004, 78, 12090–12095. 10.1128/JVI.78.21.12090-12095.2004.15479853 The overview of"/>
  <result pre="R.; SubbaraoK.; CollinsP. L.Contributions of the structural proteins of severe" exact="acute" post="respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad."/>
  <result pre="SubbaraoK.; CollinsP. L.Contributions of the structural proteins of severe acute" exact="respiratory" post="syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci."/>
  <result pre="CollinsP. L.Contributions of the structural proteins of severe acute respiratory" exact="syndrome" post="coronavirus to protective immunity. Proc. Natl. Acad. Sci. U."/>
  <result pre="ThomasS. J; MaslowJ. NSafety and immunogenicity of an anti-Middle East" exact="respiratory" post="syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm,"/>
  <result pre="J; MaslowJ. NSafety and immunogenicity of an anti-Middle East respiratory" exact="syndrome" post="coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation"/>
 </snippets>
</snippetsTree>
